Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 18, 2019
ASIT biotech presents its 2019 half year results and provides further update on its clinical programs until end-2019
ASIT biotech (ASIT.BR) (ASIT.BR) (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough allergy immunotherapy products, ...
September 18, 2019
Saniona reports positive Tesomet Phase 2a clinical results in adolescent patients with Prader-Willi syndrome
Saniona (SANION.ST), a clinical stage biotech company focused on eating disorders and CNS, today announced that adolescent as well as adult patients with Prader-Willi syndrome ...
September 18, 2019
Emmaus Life Sciences Huddles Up with SCDAAMI to Host "Sideline Sickle Cell" Community Town Hall in Detroit
TORRANCE, Calif., Sept. 18, 2019 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today that the company's ...
September 18, 2019
Avadel Pharmaceuticals Announces an Oral Presentation on Investigational Once-Nightly Sodium Oxybate (FT218) at the World Sleep 2019 Congress on September 25th
DUBLIN, Ireland, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for narcolepsy, today announced that Dr. Michael Thorpy, ...
September 18, 2019
aTyr Pharma to Participate in September Conferences
SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based ...
September 18, 2019
PolarityTE to Attend the 2019 Cantor Global Healthcare Conference
PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present at the 2019 Cantor Global ...
September 18, 2019
Pulmatrix and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating Pulmazole for Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Asthma
LEXINGTON, Mass., Sept. 18, 2019 /PRNewswire/ -- Pulmatrix, Inc. (PULM) today announced that the first patient has been dosed in the Phase 2 trial evaluating Pulmazole, an ...
September 18, 2019
Onxeo Announces Positive Intermediate Results From the First Part of the DRIIV-1b Study Evaluating AsiDNA™ in Combination With Chemotherapy
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting ...
September 18, 2019
OSE Immunotherapeutics Receives a Milestone Payment of €5.4 Million From Bpifrance for SIRPα-Antagonist Monoclonal Antibody BI 765063
NANTES, France, Sept. 18, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announces today that the Company received a €5.4 million payment ...
September 17, 2019
Santhera to Present Long-Term Data with Puldysa® (Idebenone) in Duchenne Muscular Dystrophy at Upcoming Medical Congresses
Pratteln, Switzerland, September 17, 2019 – Santhera Pharmaceuticals (SANN.SW) will present data on the therapeutic effects of long-term treatment with Puldysa® (idebenone) in Duchenne muscular dystrophy ...
September 17, 2019
AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial of Tau PET Tracer PI-2620
LAUSANNE, Switzerland, Sept. 17, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, ...
September 17, 2019
Oncolytics Biotech(R) to Present at the Ladenburg Thalmann Healthcare Conference
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 17, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic ...
September 17, 2019
Avadel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24th
DUBLIN, Ireland, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, a once-nightly formulation of sodium oxybate, for narcolepsy, ...
September 17, 2019
Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019
NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will ...
September 17, 2019
DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis
CUPERTINO, Calif., Sept. 17, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, ...
September 17, 2019
Lipocine to Present at the Ladenburg Thalmann 2019 Healthcare Conference
SALT LAKE CITY, Sept. 17, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that Dr. Mahesh Patel, ...
September 17, 2019
Immutep Announces Japanese Patent Grant for LAG525 Antibody
SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of ...
September 17, 2019
Opiant Pharmaceuticals Strengthens Management Team with Appointments of Chief Commercial Officer and General Counsel
SANTA MONICA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, ...
September 17, 2019
Yale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank’s STING Agonist Development Compound, and Radiation Therapy in Cancer at the 2019 ASTRO Annual Meeting
HOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
September 17, 2019
Orphazyme CMO to speak at FDA-funded rare disease data analytics platform launch event
Copenhagen, Denmark, September 17, 2019 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, has been invited to participate in a meeting ...
Page 1 of 162